A Phase 3 study of gedatolisib plus fulvestrant with or without palbociclib in advanced breast cancer

Active, Not Recruiting Phase 3 NCT05501886

Study Description

A study evaluating the effectiveness and safety of a combination of three drugs (gedatolisib, fulvestrant, and palbociclib) in treating advanced or metastatic breast cancer

Study Details

Registry ID:
NCT05501886
Conditions:
Breast Cancer
Phase:
Phase 3
Target Enrollment:
701 participants
Start Date:
Age Range:
18–999 years
Healthy Volunteers:
No

Study Locations (345 sites)

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →